All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2020-12-08T16:58:02.000Z

Is the Treg-engineered donor product Orca-T safe and effective at preventing aGvHD?

By Paola Frisone, Becky Gribbell
Featured
Everett H. Meyer
Dec 8, 2020
Share:

Bookmark this article

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Everett H. Meyer, Stanford University, Stanford, US. We asked, Is the Treg-engineered donor product Orca-T safe and effective at preventing acute graft-versus-host disease (GvHD)?

Is the Treg-engineered donor product Orca-T safe and effective at preventing aGvHD?

Meyer talks about the promising results of an ongoing phase II trial evaluating the safety and efficacy of Orca-T in preventing GvHD.

More about...
Acute graft-versus-host diseaseASH 2020

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
8 votes - 27 days left ...

Related articles

Add bookmark

What is new for treating acute GvHD?

During the 62nd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Ali Bazarbachi, American University of Beirut, Beirut, LB, about the new advances for treating acute GvHD.

Jan 27, 2021
Add bookmark

What is new for treating acute GvHD?

During the 62nd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Ali Bazarbachi, American University of Beirut, Beirut, LB, about the new...

Jan 27, 2021
Add bookmark

What plasma short-chain fatty acids are predictors of response to GvHD therapy?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Shernan G. Holtan, University of Minnesota, Minneapolis, US. We...

Dec 15, 2020
Add bookmark

What plasma short-chain fatty acids are predictors of response to GvHD therapy?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Shernan G....

Dec 15, 2020

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox